• Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to show a rise in quarterly revenue when it reports results on February 27 for the period ending December 31 2024

• The San Diego California-based company is expected to report a 9.2% increase in revenue to $37.367 million from $34.23 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on November 12 2024, for the period ended December 31, was for revenue between $37.00 million and $43.00 million.

• ​LSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 3 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00​, above​ its last closing price of $1.77. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated February 25 at 14:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)